Navigation Links
Vanda Pharmaceuticals Reports Third Quarter 2010 Results
Date:11/3/2010

s for tasimelteon in N24HSWD.   General and administrative (G&A) expenses were $2.1 million for the third quarter of 2010, compared to $2.8 million for the second quarter of 2010 and $5.3 million for the third quarter of 2009.  The decrease in G&A expenses in the third quarter of 2010 relative to the second quarter of 2010 is primarily due to lower non-cash stock-based compensation costs in the third quarter of 2010. Employee stock-based compensation expense recorded in the third quarter of 2010 totaled $0.8 million, compared to $1.6 million for the second quarter of 2010 and $3.3 million for the third quarter of 2009.  The decrease in employee stock-based compensation expense in the third quarter of 2010 relative to the second quarter of 2010 is the result of the cancellation of unvested options in the third quarter of 2010, which reduced the third quarter 2010 expense. -Tax provision: Vanda recorded a tax benefit of $2.3 million in the third quarter of 2010. The tax provision is based on a projected effective tax rate for 2010 applied to the year-to-date pre-tax book income with the addition or subtraction of discrete items.  The quarterly tax provision is not indicative of estimated quarterly cash tax payments. The tax provision rate applied in 2010 was determined primarily based upon a net increase in valuation allowance for excess of the deferred revenue recorded from the $200.0 million upfront milestone payment received from Novartis at the end of 2009 over the existing tax attributes utilized. The provision also includes the impact of tax credits relating to the orphan drug designation for tasimelteon. Vanda will continue to evaluate its qualified expenses for the orphan drug tax credit and, to the extent that actual qualified expenses vary significantly from Vanda's estimates, Vanda's effective tax rate will increase or decrease accordingly.  -

Our private letter ruling request to the Internal Revenue Service fr
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
2. Vanda Pharmaceuticals Reports Third Quarter 2007 Results
3. Vanda Pharmaceuticals Receives FDA Acceptance of Iloperidone New Drug Application
4. Vanda Presents Phase III Iloperidone Efficacy Data
5. Phase III Data Show Vanda Pharmaceuticals Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
6. Vanda Pharmaceuticals Provides Update on Iloperidone
7. Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet
8. FDA Approves Vanda Pharmaceuticals Fanapt(TM) for the Treatment of Schizophrenia
9. Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt(TM) in the U.S. and Canada for the Treatment of Schizophrenia
10. Vanda Pharmaceuticals Announces Expiration of Hart-Scott -Rodino Waiting Period for Exclusive License of Fanapt(TM)
11. Vanda Pharmaceuticals Announces U.S. Patent Allowance for a Long-Acting Injectable Formulation of Fanapt(TM) (iloperidone) in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 2014 HeartWare International, Inc . (NASDAQ: ... miniaturized circulatory support technologies that are revolutionizing the treatment ... revenues for the fourth quarter of 2013 will be ... approximately $208 million. "Our full-year revenue growth ...
(Date:1/14/2014)... HARRISBURG, Pa. , Jan. 14, 2014 Dynamic Healthcare ... ("GMH"), announced today that it acquired Progressive Home Medical Equipment, ... January 7, 2014. The terms of the acquisition were not ... medical equipment ("DME") company providing a wide range of sleep, ...
(Date:1/14/2014)... 2014 NineSigma , Inc., the leading innovation ... Leadership Summit , May 14-16, 2014 at the Global ... . This is the premier ... breakthrough achievements through open innovation. Participants will learn how ...
Breaking Medicine Technology:HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4
... letter is being released by CEL-SCI Corporation (NYSE Alternext ... Shareholders: , I am writing today to provide you with ... on our plans for dealing with the current financial downturn. ... year of meaningful accomplishments which put CEL-SCI in a valuable ...
... Md., Feb. 19 Hospital associations in 10 ... program to test methods of reducing central-line associated ... (ICUs), according to HHS, Agency for Healthcare Research ... Nebraska, North Carolina, Ohio, Pennsylvania, Texas, and Washington. ...
Cached Medicine Technology:CEL-SCI Corporation Releases Letter to Shareholders 2CEL-SCI Corporation Releases Letter to Shareholders 3CEL-SCI Corporation Releases Letter to Shareholders 4CEL-SCI Corporation Releases Letter to Shareholders 510-State Project to Study Methods to Reduce Central Line-Associated Bloodstream Infections in Hospital ICUs 210-State Project to Study Methods to Reduce Central Line-Associated Bloodstream Infections in Hospital ICUs 3
(Date:4/18/2014)... prepped to enter the battle against infectious disease. ... in remote areas, thanks in part to knowledge ... International Space Station on the behavior of liquids. ... flow to diagnose infectious diseases such as HIV/AIDS ... at Northwestern University in Evanston, Ill., had been ...
(Date:4/18/2014)... of Medicine researchers have been awarded two-year grants for ... announced this month. Of the 110 initial submissions to ... Forum Program, only four projects were funded, three of ... Jonathan Powell, M.D., Ph.D.; G. William Wong, Ph.D.; and ... professor of oncology, will use his $500,000 proof of ...
(Date:4/18/2014)... University psychologists have made a brain-related discovery that ... disorders. , This discovery opens up the possibility ... suppress a specific brain activity that the researchers ... The Journal of Neuroscience has just ... McDonald, an associate professor of psychology and his ...
(Date:4/18/2014)... Northwestern Medicine scientists could lead to potential new treatments ... with scleroderma. , Fibrosis, or scarring, is a ... skin and lungs can lead to serious organ damage ... new therapeutic options centers on findings made by Swati ... the role that a specific protein plays in promoting ...
(Date:4/17/2014)... identified the first genetic variant specifically associated with ... for around 10-15 per cent of all breast ... the breast cancer sub-type, called invasive lobular carcinoma, ... of this particular kind of breast cancer, which ... published today (Thursday) in the journal PloS ...
Breaking Medicine News(10 mins):Health News:Space-tested fluid flow concept advances infectious disease diagnoses 2Health News:Space-tested fluid flow concept advances infectious disease diagnoses 3Health News:Scientists discover brain's anti-distraction system 2Health News:New clues on tissue scarring in scleroderma 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3
... America, Inc.,(OTC Bulletin Board: CBAI), the umbilical cord ... on bringing the life,saving potential of stem cells ... for the first quarter of 2008, ended March ... umbilical cord,blood storage business increased 10 percent while ...
... 20 Accelerate Brain Cancer,Cure ( http://www.abc2.org ) ... brain cancer specialists covering important updates on,advancements in ... for newly,diagnosed brain cancer patients., The videos ... the worlds,leading researchers in the fields of brain ...
... May 20 Mayo Clinic researchers,found that the ... is approximately the same at a,multidisciplinary medical center ... rate for 211 hospitals in the National Healthcare ... because it suggests that,care levels are generally strong ...
... Data presented today at the International Conference ... that Perforomist™ Inhalation Solution (formoterol fumarate inhalation ... profile that is comparable to the dry ... Foradil® Aerolizer® 12 g (FA). , ...
... The Board of,Directors of BD (Becton, Dickinson and Company) ... 28.5 cents per common share. The dividend will be,payable ... June 9, 2008. The,indicated annual dividend rate is $1.14 ... global medical technology company that manufactures and,sells medical devices, ...
... the following statement today following reports on Senator Ted,Kennedy,s ... been met with great concern., "Senator Kennedy is ... a,great fighter for America,s children, workers and seniors., ... well in this,challenge., "Our thoughts and prayers are ...
Cached Medicine News:Health News:Cord Blood America Reports First Quarter Financial Results; Gross Profits Increase 2Health News:Brain Cancer Science and Treatment Information 2Health News:Mayo Clinic Research Shows U.S. Intensive Care Units' Prevention of Pneumonia in Critically-ill Patients Generally Strong; Identifies Area of Improvement 2Health News:Mayo Clinic Research Shows U.S. Intensive Care Units' Prevention of Pneumonia in Critically-ill Patients Generally Strong; Identifies Area of Improvement 3Health News:Perforomist-comparable pharmacokinetic and pharmacodynamic profile to DPI formulation 2
... system is an automated solution that identifies the patient, tying all critical information to the patient's unique bar-coded ... ... ... ...
The Metrologic MS9520 Voyager is a high performance single line laser bar code scanner with automatic activation and sophisticated data transmission via Metrologic proprietary CodeGate technology....
... direct thermal wristband ideal for positive ... admissions. Its clip closures provide a ... white for color coding. Designed specifically ... peak performance. Print high-quality text and ...
... The DataMate Laser ... System consists of laser-printable ... closure wristband and laser ... paperwork. The wristbands clear, ...
Medicine Products: